CLDX vs CTY: fair value comparison
Celldex Therapeutics, Inc. and City Therapeutics, Inc. · Updated 2026-10-26
CLDX has no fair-value estimate yet: no usable analyst consensus or too few reported quarters. CTY has no fair-value estimate yet: no usable analyst consensus or too few reported quarters. Within Healthcare, CLDX currently ranks higher by quality score.
| CLDX | CTY | |
|---|---|---|
| Verdict | No estimate yet | No estimate yet |
| Last price | $29.25 | $20.77 |
| 12-month range | $22.58–$44.87 | — |
| Rank by discount to fair value | — | — |
| Rank by quality score | #181 of 302 Healthcare | #183 of 302 Healthcare |
| Quality grade | F | F |
| Leverage | Low | Low |
| Margin trend | Contracting | Contracting |
| Revenue growth | Declining | Declining |
| RSI zone | Neutral | — |
| 50/200-day trend | Mixed | — |
| 52-week position | The lower-middle quarter | — |
Full single-stock breakdowns: CLDX fair value analysis · CTY fair value analysis